Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Baseline physiological data from anesthetized pigs in a VX intoxication model.

Toxicology letters·2024

Same author

Pleural adenosine deaminase cut-off value for the diagnosis of tuberculous pleural effusion using the Diazyme assay.

Hong Kong medical journal = Xianggang yi xue za zhi·2018

Same author

[Plasmodium knowlesi: an emerging species in humans?].

Medecine et sante tropicales·2013

Same author

[Propylthiouracil-induced multispecific antineutrophil cytoplasmic antibodies].

La Revue de medecine interne·2010

Same author

[Value of assaying adenosine deaminase level in patients with neuromeningeal tuberculosis].

Medecine tropicale : revue du Corps de sante colonial·2010

Same author

[The old man and the syrup].

Pathologie-biologie·2009

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

[Fondaparinux: the present and the future].

C Garcia Hejl¹, C Garcia, H Thefenne-Astier

¹Laboratoire de biochimie, HIA Val-de-Grâce, 74, boulevard Port-Royal, 75005 Paris, France. carinegarcia92@wanadoo.fr

Pathologie-Biologie

|January 8, 2008

Summary

New antithrombotic drugs inhibiting factor Xa, like fondaparinux, are effective and safe for preventing and treating thromboembolic diseases. These agents offer simplified anticoagulant therapy management for patients.

Related Experiment Videos

Last Updated: Jul 8, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Area of Science:

Pharmacology
Hematology
Clinical Medicine

Background:

Thromboembolic diseases pose significant health risks.
Anticoagulant therapies are crucial for managing these conditions.

Purpose of the Study:

To evaluate the effectiveness and safety of new antithrombotic molecules.
To explore the therapeutic potential of fondaparinux and other anti-Xa inhibitors.

Main Methods:

Review of clinical trials on antithrombotic agents.
Analysis of fondaparinux and novel anti-Xa inhibitors' properties.

Main Results:

Fondaparinux (Arixtra) demonstrates efficacy and safety in preventing thromboembolic events post-surgery.
It is also effective in treating pulmonary embolism, deep vein thrombosis, and acute myocardial infarction.
New anti-Xa inhibitors show promise in antithrombotic therapy.

Conclusions:

Fondaparinux offers a safe and effective option for thromboembolic disease management.
These agents may simplify the treatment of patients requiring anticoagulation.